China is expanding restrictions on foreign acquisitions and technology transfers, a move that follows the blocked investment by Meta in the Chinese AI startup Manus, Reuters reports.

The regulatory shift directly affects R&D managers at multinational firms with Chinese partnerships, joint laboratories or licensing arrangements. Any deal involving outbound technology transfer or inbound foreign capital into sensitive sectors now faces a longer and less predictable approval path.

The most concrete trigger in the timeline: Chinese authorities blocked Meta's proposed investment in Manus, the AI agent developer that attracted international attention earlier this year. That rejection signaled that even minority foreign stakes in strategically relevant Chinese AI companies now sit under active review.

For corporate R&D portfolio planners, the implications are operational rather than abstract. Deals that once closed on standard timelines may stall in review. Licensing Chinese-developed AI models, algorithms or dual-use components into foreign products could require new approvals, and the definition of what counts as restricted technology appears to be widening.

Universities and research institutes with China-based collaborations should review existing agreements now. Co-development contracts, material transfer agreements and jointly owned intellectual property are the categories most likely to draw scrutiny as enforcement details emerge.

Reuters reports the curbs as an expansion of existing rules rather than an entirely new regime, so firms already compliant with earlier foreign-investment screening requirements will find familiar procedural ground — but with a broader perimeter of covered transactions.

What remains unclear from the reporting is the precise scope: which technology categories fall under the expanded transfer controls, and what thresholds trigger mandatory filing. Companies with pending transactions should expect case-by-case guidance until implementing regulations are published.

Watch for follow-on implementing rules and any official statement quantifying which sectors the expanded review covers.